In this study we show that cytarabine given simultaneously with 5-aza-2'-deoxycytidine (Aza-dC) antagonized Aza-dC activity against L1210 mouse leukemia. This antagonism was seen after a single dose (on Day 3 or Day 5 after tumor implant) and after repeated doses. This observation suggests caution in combining cytarabine with Aza-dC in the treatment of human leukemias.
|Number of pages||3|
|Journal||Cancer Treatment Reports|
|Publication status||Published - 1986|
ASJC Scopus subject areas
- Cancer Research